AlphAIAlphAI — Financial news for AI agents
benzinga.comSEP 142 min read$COIN

This Coinbase Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday - Coinbase Global (NASDAQ:

Compass Point upgraded Coinbase (COIN) to Neutral with a $177 price target, up from $130. Other upgrades include 4D Molecular Therapeutics (FDMT), Affirm (AFRM), Chime Financial (CHYM), and Bullish (BLSH) by their respective analysts. COIN closed at $175.26 on Friday.

Original reporting
benzinga.com
Published Sep 14, 2026, 12:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 3:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$COIN
Bullish
medium confidence
Mentioned
$COIN · $FDMT · $AFRM · $CHYM · $BLSH
Relevance
7/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$COINBullishMed
01

Why it matters

Upgrades provide fresh valuation guidance and may trigger short‑term price moves as investors adjust positions.

02

Market read

The upgrades collectively suggest a bullish tilt in analyst sentiment for mid‑cap growth stocks, potentially prompting buying pressure.

03

What to watch

Potential regulatory risks for crypto‑related firms and clinical trial timelines for biotech firms.

Relevance 7/10Novelty 7/10Timing: Monday

Background

The article compiles recent analyst rating upgrades for five U.S.-listed companies across fintech, crypto, and biotech.

Company-level read

Ticker impact

$COINBullishMedium confidence
Context

Compass Point analyst upgraded Coinbase (COIN) from Sell to Neutral with a $177 price target.

Expected impact

Potential upside toward $177 target.

Evidence & confidence

Analyst raised target reflecting better market conditions for the crypto exchange.

$FDMTBullishMedium confidence
Context

Cantor Fitzgerald analyst upgraded 4D Molecular Therapeutics (FDMT) from Neutral to Overweight with a $20 price target.

Expected impact

Shares may rally toward $20 target.

Evidence & confidence

Higher rating and target reflect positive expectations for upcoming data.

$AFRMBullishMedium confidence
Context

Wolfe Research analyst upgraded Affirm (AFRM) from Peer Perform to Outperform with a $90 price target.

Expected impact

Potential price appreciation toward $90.

Evidence & confidence

Analyst sees stronger growth prospects and improved profitability.

$CHYMBullishMedium confidence
Context

Rothschild & Co analyst upgraded Chime Financial (CHYM) from Neutral to Buy with a $46 price target.

Expected impact

Shares could move toward $46.

Evidence & confidence

Analyst expects continued user acquisition and revenue expansion.

$BLSHBullishMedium confidence
Context

Compass Point analyst upgraded Bullish (BLSH) from Neutral to Buy with a $51 price target.

Expected impact

Potential upside toward $51.

Evidence & confidence

Higher target driven by anticipated earnings growth.

Market effects

Sector

Analyst upgrades may lift sentiment across fintech and biotech sectors.

Regional

U.S. market participants likely to react positively to the upgrades.

Global

Positive rating changes could influence global investor perception of U.S. growth stocks.

Counterpoint

What could challenge this read

Some investors may view the upgrades as premature given broader market volatility.

Key entities

  • company
    Coinbase Global Inc

    US‑listed crypto exchange (COIN).

  • company
    4D Molecular Therapeutics Inc

    Biotech firm (FDMT).

  • company
    Affirm Holdings Inc

    Buy‑now‑pay‑later provider (AFRM).

  • company
    Chime Financial Inc

    Neobank (CHYM).

  • company
    Bullish

    Financial services firm (BLSH).

Read at source← All news

Related articles

SEP 14
$COINMed

Why is Coinbase stock surging today?

Coinbase (COIN) stock rose 7.5% on regulatory optimism ahead of a U.S. Senate vote on the Digital Asset Market Clarity Act. Analysts upgraded COIN, with Compass Point raising its target to $177 and Goldman Sachs to $219. Bitcoin also gained, supporting the rally. The S&P 500 and Nasdaq declined 0.5% and 0.8%, respectively.

investing.com4 min
SEP 13
$COINMed

Morgan Stanley makes its first call on major crypto stock

Morgan Stanley initiated coverage of Coinbase Global (COIN) with an 'Equal Weight' rating and $250 price target, citing its expansion into broader financial services. Coinbase's Q2 results showed 10.3% crypto trading market share and 88% of net revenue from non-Bitcoin sources. The stock was trading at $175.20, up 1.7% on the day.

yahoo.com2 min
SEP 12
$AFRMMedAI 8/10

Goldman Sachs Is Bullish. Here Are 3 Reasons AFRM Stock Could Climb 69%.

Goldman Sachs and other firms raised their price targets for Affirm (AFRM), with a mean target of $99.48 and a high of $124. The company reported strong Q4 results, with interest income up 30% YOY and net income reaching $1.6 billion. Growth was driven by the Affirm Card, which saw active cardholders double and GMV surge 124%. The company also has significant growth potential in expanding its merchant network and new markets.

inkl.com3 min